← Leaderboards
Alan D Miller
Tulane University Of Louisiana
$108,322
Attributed
$108,322
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.7K · FY2005–06$5K$3.8K$2.5K$1.3K$0
'05
'06
Funding mix
By agency
NIH$108,322 · 6
By mechanism
P30$100,127 · 1
M01$8,195 · 5
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Eugene A Woltering$73,643
- Paul O Schwarzenberger$3,319,899
- Ellen L Zakris$642,522
- William McKinnon$49,515
- Raja Mudad$10,986
Others in their field
Top investigators on “Chemoprevention”
- Charles A Coltman · Southwest Oncology Group$144,723,158
- Norman Wolmark · Nsabp Foundation, Inc.$110,141,959
- John Anthony Baron · Dartmouth College$61,176,184
- Fred M Gordin · Social And Scientific Systems, Inc.$50,695,408
- Caroline C Sigman · Ccs Associates, Inc.$26,419,788
- Jonathan White · Midwest Research Institute$24,635,824
Research focus
ChemopreventionClinical ResearchClinical Trial Phase IiiDietary SupplementsDietary Trace ElementHuman MortalityHuman SubjectHuman Therapy EvaluationLongitudinal Human StudyNeoplasm /Cancer Nutrition TherapyNeoplasm /Cancer Relapse /RecurrenceNeoplasm /Cancer SurgeryNonsmall Cell Lung CancerNutrition Aspect Of CancerNutrition Related TagPatient Oriented ResearchQuestionnairesSelenium
Grant awards (7)
GEMCITABINE AND CAPECITABINE IN UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA$2,525
M01 · FY2006 · RR · contact PI
TRIAL OF ABVD VS STANFORD V =/- RADIATION THERAPY IN HODGKIN'S DISEASE$583
M01 · FY2006 · RR · contact PI
SWOG S0124: RANDOMIZED PHASE III TRIAL OF CISPLATIN AND IRINOTECAN (NSC-616348)$4,141
M01 · FY2005 · RR
GEMCITABINE AND CAPECITABINE IN UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA$444
M01 · FY2005 · RR
SWOG E5597: PHASE III CHEMOPREVENTION TRIAL OF SELENIUM SUPPLEMENTATION IN NSCLC$148
M01 · FY2005 · RR
Administrative Core$100,127
P30 · FY2004 · DK
SWOG E5597: Phase III Chemoprevention Trial of Selenium Supplementation in NSCLC$354
M01 · FY2004 · RR